2245953-10-8
2245953-10-8
Chemical Structure
Dazodalibep
Synonym(s): MEDI 4920; VIB 4920
- CAS No.: 2245953-10-8
- Formula:N/A
- Molecular Weight:(87.82 kDa)
IUPAC Name: 4-bromothieno[2,3-b]pyridine
SMILES: [Dazodalibep]
Biological Activity: Dazodalibep (MEDI 4920; VIB 4920) is a non-antibody fusion protein that targets CD40L. Dazodalibep inhibits the co-stimulatory signals between immune cells (such as T cells, B cells, and antigen-presenting cells), thereby enabling the inhibition of a broader range of cellular and humoral responses. Dazodalibep can be used for research on rheumatoid arthritis and Sjögren's syndrome[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Dazodalibep | 99% | Dazodalibep (MEDI 4920; VIB 4920) is a non-antibody fusion protein that targets CD40L. Dazodalibep inhibits the co-stimulatory signals between immune cells (such as T cells, B cells, and antigen-presenting cells), thereby enabling the inhibition of a broader range of cellular and humoral responses. Dazodalibep can be used for research on rheumatoid arthritis and Sjögren's syndrome. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. St Clair EW, et al. CD40 ligand antagonist dazodalibep in Sjögren's disease: a randomized, double-blinded, placebo-controlled, phase 2 trial. Nat Med. 2024 Jun;30(6):1583-1592. [Content Brief]
- [2]. Pham TH, et al. AB0746 CD40L BLOCKADE WITH DAZODALIBEP SIGNIFICANTLY IMPROVES DISEASE ACTIVITY, SWOLLEN AND TENDER JOINT COUNTS, WHILE REDUCING MULTIPLE T-AND B-CELL BIOMARKERS IN THE MIDORA PHASE 2 STUDY OF PATIENTS WITH MODERATE-TO-SEVERE ACTIVE RHEUMATOID ARTHRITIS. Annals of the Rheumatic Diseases. 2024 Jun 1;83:1664-5.
Keywords
